cabacitaxel

DRUG2 trials

Sponsors

Tampere University Hospital, GBG Forschungs GmbH

Conditions

Metastatic Prostate CancerPrimary Breast Cancer

Phase 2

Second-line Chemotherapy in Castration Resistant Prostate Cancer

CompletedNCT01558219

Tampere University HospitalMetastatic Prostate Cancer

Start: 2011-11-30End: 2014-12-31Updated: 2016-10-21

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

CompletedNCT01779479

GBG Forschungs GmbHPrimary Breast Cancer

Start: 2013-02-28End: 2016-02-29Updated: 2017-08-01

Related Papers

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

2017-07-3016 citations

Biweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: Final analysis of Prosty II trial.

Journal of Clinical Oncology2016-05-202 citations

Biweekly cabazitaxel as post-docetaxel treatment for metastatic castration resistant prostate cancer (mCRPC): Findings from an early safety analysis of the Prosty II trial.

Journal of Clinical Oncology2015-03-013 citations